Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exemestane for primary prevention of breast cancer in postmenopausal women.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 15 Aug 2012

Zhang Yang, Simondsen Katherine, Kolesar Jill M

Abstract excerpt

PURPOSE: The benefits and risks of exemestane for the primary prevention of breast cancer are discussed and compared with other breast cancer chemoprevention therapies. SUMMARY: Selective estrogen-receptor modulators (SERMs) are the current mainstay for primary prevention of breast cancer. As an alternative, exemestane, an aromatase inhibitor, has been evaluated for breast cancer prevention in postmenopausal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstadienes
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aromatase Inhibitors

Share to Chemoprevention

Share to Estrogen Antagonists

Share to Primary Prevention

Share to Selective Estrogen Receptor Modulators

Share to Tamoxifen

Source

Identifiers

PMID: 22855103
DOI: 10.2146/ajhp110585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exemestane for primary prevention of breast cancer in postmenopausal women.PMID 22855103Read ↗

The potential for aromatase inhibition in breast cancer prevention.Semantic proximity Read ↗

Hormonal prevention of breast cancer.Semantic proximity Read ↗

Preventing breast cancer in high-risk women, 2008.Semantic proximity Read ↗

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.Semantic proximity Read ↗

A Phase II Trial of the JAK-Inhibitor Ruxolitinib with Exemestane for Estrogen Receptor Positive, Aromatase Inhibitor Resistant, Advanced Breast CancerSemantic proximity Read ↗

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.Semantic proximity Read ↗

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.Semantic proximity Read ↗

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.Semantic proximity Read ↗

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.Semantic proximity Read ↗

The menopause, hormone replacement therapy and breast cancer.Semantic proximity Read ↗

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.Semantic proximity Read ↗

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.